BARCELONA, Spain, June 24 /PRNewswire/ -- Spanish biotechnology company Progenika Biopharma, specializing in the development of personal medicine technology, has granted Grifols exclusive world-wide distribution rights for its BLOODCHIP® molecular biology products. BLOODCHIP® products are used for genotyping of blood donors to assure the compatibility of blood for transfusion between donor and recipient.
Under this agreement, Grifols takes a further step towards the consolidation of its Diagnostic division, expanding its range of products at the leading edge of immunohematology technology. In addition, Grifols' presence in more than 90 countries will global distribution of the BLOODCHIP® product line. Likewise, the international presence of Grifols in more than 90 countries through the 22 Grifols' affiliates assures effective global distribution of the test.
The new product line is expected to generate revenues of between euro 50 and euro 100 million over the next 5 years. Although the use of molecular biology tests in transfusion compatibility is still at its early stages, its use is expected to become more widespread as a result of the hemovigilance and transfusion safety plans being introduced in many countries.
Victor Grifols, President and CEO of Grifols stated: "This agreement will allow us to strengthen our Diagnostic Division and consolidate our global position in the field of blood grouping with a new innovative tool that increases transfusion safety." For his part, Antonio Martinez, CEO of Progenika, noted that, "This distribution agreement ensures that our products will be properly marketed, and allows us to focus on the development of new diagnostic and therapeutic tools that
|SOURCE Grifols, Inc.|
Copyright©2010 PR Newswire.
All rights reserved